TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18846799

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PVP) performed by injecting polymethylacrylate in the diseased vertebral body.
Number of subjects: 24
Study: 15946597

Group type: EXPERIMENTAL
Intervention: 100 mg Cloril tablet (Test formulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 100 mg Clozaril tablet (Reference formulation)
Number of subjects: 0
Study: 11942772

Group type: COMPARATOR
Intervention: Gemfibrozil (900 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (200 mg)
Number of subjects: 21
Study: 11316966

Group type: EXPERIMENTAL
Intervention: Azelastine (4 mg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Ebastine (10 mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 10322842

Group type: EXPERIMENTAL
Intervention: Baoyuan Qiangshen (BQ) II tablet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Essential amino acid added capoten
Number of subjects: 40
Study: 8295088

Group type: EXPERIMENTAL
Intervention: 6% ferric oxalate in 0.9% saline
Number of subjects: 25

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 25
Study: 3098129

Group type: EXPERIMENTAL
Intervention: 4% sodium cromoglycate (SCG) in an oil-in-water cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: Matching placebo cream
Number of subjects: 40
Study: 29098469

Group type: EXPERIMENTAL
Intervention: Dietary arachidonic acid (ARA) levels from 1 to 6% of total fatty acids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control diet with total fish oil replacement and defatted fish meal containing 0.1-g ARA g‐1 diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary ARA levels
Number of subjects: 0
Study: 28933745

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (160 mg/day for six weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 25816377

Group type: EXPERIMENTAL
Intervention: Experimental consultation room design (pedestal table replacing examination table)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional consultation room design
Number of subjects: 0
Study: 24244261

Group type: EXPERIMENTAL
Intervention: lenalidomide plus cetuximab combination therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: lenalidomide 25 mg/day monotherapy
Number of subjects: 51
Study: 21146636

Group type: EXPERIMENTAL
Intervention: Phased individually-tailored 10-week walking program
Number of subjects: 154

Group type: COMPARATOR
Intervention: Maintain usual activity (Control)
Number of subjects: 154
Study: 18308007

Group type: EXPERIMENTAL
Intervention: Decreased right ventricular fractional area change (RVFAC)
Number of subjects: 605
Study: 16556245

Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) increase
Number of subjects: 21337

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) increase
Number of subjects: 21337

Group type: EXPERIMENTAL
Intervention: Pulse Pressure increase
Number of subjects: 21337

Group type: COMPARATOR
Intervention: Comparison of BP between migraine patients and controls
Number of subjects: 21337
Study: 12656878

Group type: EXPERIMENTAL
Intervention: Oral surgeon
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Surgical assistant
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prosthodontist
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral surgeon (total time including unscheduled visits)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Surgical assistant (total time including unscheduled visits)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prosthodontist (total time including unscheduled visits)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Unscheduled visits
Number of subjects: 30
Study: 14733634

Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (HDCP) 100 mg/m2
Number of subjects: 83

Group type: COMPARATOR
Intervention: Moderate-dose cisplatin (MDCP) 50 mg/m2 combined with ifosfamide (3 g/m2) and mitomycin (6 mg/m2)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (HDCP)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Moderate-dose cisplatin (MDCP)
Number of subjects: 83
Study: 8960474

Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin (100 mg per square meter) plus intravenous cyclophosphamide (600 mg per square meter)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Intravenous cisplatin (100 mg per square meter) plus intravenous cyclophosphamide (600 mg per square meter)
Number of subjects: 546
Study: 1285270

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Baseline plasma levels of MHPG and HVA
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Clinical assessment using Hamilton depression rating scale and BPRS
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Plasma catabolites MHPG, 5‐HIAA, HVA
Number of subjects: 47
Study: 29630752

Group type: EXPERIMENTAL
Intervention: Automatic rapid-inflation (RI) system
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Manual handheld pump and sphygmomanometer (HS) system
Number of subjects: 18

Group type: COMPARATOR
Intervention: Automatic personalized tourniquet (PT) system
Number of subjects: 18
Study: 27558507

Group type: EXPERIMENTAL
Intervention: Edoxaban with foot pump
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Edoxaban without foot pump
Number of subjects: 124

Group type: COMPARATOR
Intervention: Fondaparinux
Number of subjects: 124
Study: 25609549

Group type: EXPERIMENTAL
Intervention: Raisins
Number of subjects: 51

Group type: COMPARATOR
Intervention: Alternative processed snacks
Number of subjects: 51
Study: 23632669

Group type: EXPERIMENTAL
Intervention: Bipolar hemiarthroplasty (HA)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Novel total hip replacement (PCU-THR)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Functional outcome assessed with the Harris hip score (HHS)
Number of subjects: 96
Study: 20628363

Group type: EXPERIMENTAL
Intervention: Fujinon intelligent chromoendoscopy (FICE)
Number of subjects: 1318

Group type: COMPARATOR
Intervention: White light imaging
Number of subjects: 1318

Group type: EXPERIMENTAL
Intervention: FICE
Number of subjects: 1318
Study: 18245509

Group type: EXPERIMENTAL
Intervention: Surgical interventions
Number of subjects: 30
Study: 16643193

Group type: EXPERIMENTAL
Intervention: Isometric training at 100 degrees (longer muscle length: LT)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Isometric training at 50 degrees (shorter muscle length: ST)
Number of subjects: 9
Study: 12600848

Group type: COMPARATOR
Intervention: Whole-grain breakfast cereal intake (>= 1 serving/day)
Number of subjects: 86190

Group type: COMPARATOR
Intervention: Refined-grain breakfast cereal intake
Number of subjects: 86190

Group type: COMPARATOR
Intervention: Total breakfast cereal intake
Number of subjects: 86190
Study: 11020403

Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 117

Group type: COMPARATOR
Intervention: Ahmed implant
Number of subjects: 117

Group type: COMPARATOR
Intervention: Trabeculectomy and Ahmed implant
Number of subjects: 117
Study: 8795090

Group type: EXPERIMENTAL
Intervention: Epinephrine (20 ng/kg per min for 30 min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Norepinephrine (40 ng/kg per min for 30 min)
Number of subjects: 8
Study: 1290733

Group type: EXPERIMENTAL
Intervention: Large-volume spacers (Nebuhaler, Volumatic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breath actuated dry-power inhalers (Rotahaler, Diskhaler, Turbohaler)
Number of subjects: 0
Study: 6695826

Group type: EXPERIMENTAL
Intervention: Criticare HN
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vivonex HN
Number of subjects: 12
Study: 31744345

Group type: EXPERIMENTAL
Intervention: CML-enriched maternal milk formulation (8 mg GA per day)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Control maternal milk formulation (4 mg GA per day)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: No maternal milk supplementation with standard obstetric care
Number of subjects: 1500
Study: 30992195

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg) and Saxagliptin (2.5 mg)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 461
Study: 27896805

Group type: EXPERIMENTAL
Intervention: Family intervention addressing expressed emotion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-family home sessions
Number of subjects: 0
Study: 28101379

Group type: EXPERIMENTAL
Intervention: Metformin treatment for 18 months in daily practice
Number of subjects: 19

Group type: COMPARATOR
Intervention: Metformin treatment for 18 months in RCT
Number of subjects: 19
Study: 24699854

Group type: EXPERIMENTAL
Intervention: Soy-dairy protein blend
Number of subjects: 16

Group type: COMPARATOR
Intervention: Whey protein
Number of subjects: 16
Study: 22580119

Group type: EXPERIMENTAL
Intervention: Skin-sparing helical tomotherapy (HT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 3D-conformal radiotherapy (3D-CRT)
Number of subjects: 50
Study: 20865876

Group type: COMPARATOR
Intervention: 4 mg x kg(‐1) ketamine, 0.5 mg x kg(‐1) midazolam, 0.02 mg x kg(‐1) atropine
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 8 mg x kg(‐1) ketamine, 0.5 mg x kg(‐1) midazolam, 0.02 mg x kg(‐1) atropine
Number of subjects: 67
Study: 16822792

Group type: EXPERIMENTAL
Intervention: Ultrapure dialysate (UPD)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional dialysate (CD)
Number of subjects: 78
Study: 15144492

Group type: EXPERIMENTAL
Intervention: Visual preference procedures for 6- and 7-month-olds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual preference procedures for 3- to 4-month-olds
Number of subjects: 0
Study: 11061280

Group type: EXPERIMENTAL
Intervention: Prednisone (20 mg daily for 4 weeks, then 10 mg daily for 1 year, followed by gradual withdrawal over 16 weeks)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 138
Study: 9068508

Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 8375267

Group type: EXPERIMENTAL
Intervention: Bovine NPH insulin
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Human NPH insulin
Number of subjects: 29
Study: 3503120

Group type: EXPERIMENTAL
Intervention: Eyelid closure (ELC)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nasolacrimal occlusion (NLO)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal blinking (Control)
Number of subjects: 8
Study: 29804485

Group type: EXPERIMENTAL
Intervention: SPF 30 sunblock stick
Number of subjects: 20

Group type: COMPARATOR
Intervention: No sunblock protection
Number of subjects: 20
Study: 27696732

Group type: EXPERIMENTAL
Intervention: Remission according to ACR/EULAR criteria at single visits (13, 26, 39, or 52 weeks)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Remission according to ACR/EULAR criteria at consecutive visits (13 and 26, 26 and 39, or 39 and 52 weeks)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Remission according to ACR/EULAR criteria at single visits
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Remission according to ACR/EULAR criteria at consecutive visits
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Remission according to ACR/EULAR criteria
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Single DAS remission
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Sustained remission periods
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: (Sustained) remission
Number of subjects: 144
Study: 26383996

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Treatment change candidates at week 12
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Treatment change candidates at week 24
Number of subjects: 1185
Study: 23394146

Group type: EXPERIMENTAL
Intervention: Double-blind placebo-controlled food challenge (DBPCFC)
Number of subjects: 116
Study: 21252061

Group type: EXPERIMENTAL
Intervention: Carboplatin and gemcitabine (CG)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Carboplatin and paclitaxel (CP)
Number of subjects: 181
Study: 19583678

Group type: EXPERIMENTAL
Intervention: Homozygous for Arg92 allele
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Day 7 survivors
Number of subjects: 52
Study: 17456913

Group type: EXPERIMENTAL
Intervention: 20% azelaic acid gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vehicle gel (placebo)
Number of subjects: 60
Study: 15868618

Group type: EXPERIMENTAL
Intervention: Human recombinant relaxin treatment
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Health Assessment Questionnaire Disability Index (HAQ‐DI)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: SF‐36
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: HAQ‐DI
Number of subjects: 239
Study: 12537345

Group type: EXPERIMENTAL
Intervention: GCB+D (Gluma Comfort Bond + Desensitizer)
Number of subjects: 119

Group type: COMPARATOR
Intervention: GCB (Gluma Comfort Bond)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: GCB (Gluma Comfort Bond) with rescue treatment using Gluma Desensitizer
Number of subjects: 119
Study: 9708388

Group type: EXPERIMENTAL
Intervention: Intrasheath injection
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Mixed sheath and subcutaneous injection
Number of subjects: 95

Group type: COMPARATOR
Intervention: Subcutaneous injection
Number of subjects: 95
Study: 8570768

Group type: EXPERIMENTAL
Intervention: meta-chlorophenylpiperazine (m-CPP)
Number of subjects: 67

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: m-CPP
Number of subjects: 67
Study: 2223415

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 81
Study: 357754

Group type: EXPERIMENTAL
Intervention: brompheniramine maleate and phenylpropanolamine hydrochloride (Lunerin mite)
Number of subjects: 44
Study: 31179500

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) <110 mmHg
Number of subjects: 3598

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) 130 - <140 mmHg
Number of subjects: 3598

Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) 60 - <70 mmHg
Number of subjects: 3598

Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) 80 - <90 mmHg
Number of subjects: 3598
Study: 28730950

Group type: EXPERIMENTAL
Intervention: Lying flat (0°) head positioning
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sitting up (≥30°) head positioning
Number of subjects: 140
Study: 25703461

Group type: EXPERIMENTAL
Intervention: 100 kVp tube voltage with iDose algorithm (group B)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 100 kVp tube voltage with non-tagged algorithm (group B)
Number of subjects: 98

Group type: COMPARATOR
Intervention: 120 kVp tube voltage with standard filtered back projection (FBP) algorithm (group A)
Number of subjects: 98
Study: 23213072

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention for six months
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention for six months (among those reaching 80% of intervention goal)
Number of subjects: 75
Study: 20926981

Group type: EXPERIMENTAL
Intervention: Blood volume analysis in addition to pulmonary artery catheter parameters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pulmonary artery catheter alone
Number of subjects: 0
Study: 18683898

Group type: COMPARATOR
Intervention: Binge eating disorder pharmacotherapy trials (specific interventions not detailed in the abstract)
Number of subjects: 2685

Group type: EXPERIMENTAL
Intervention: Exclusionary psychotropic medication
Number of subjects: 2685

Group type: EXPERIMENTAL
Intervention: BED criteria
Number of subjects: 2685

Group type: EXPERIMENTAL
Intervention: Age and weight range
Number of subjects: 2685

Group type: EXPERIMENTAL
Intervention: Prohibited medical or psychiatric disorders
Number of subjects: 2685

Group type: EXPERIMENTAL
Intervention: Weight loss programmes
Number of subjects: 2685
Study: 16423672

Group type: EXPERIMENTAL
Intervention: Inferior myocardial infarction (MI)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Anterior myocardial infarction (MI)
Number of subjects: 16
Study: 15627931

Group type: EXPERIMENTAL
Intervention: Palpebral hygiene solution used for 3 days
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Palpebral hygiene solution used for 4 days
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Palpebral hygiene solution used for 5 days
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Palpebral hygiene solution used for 6 days
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control group (no product used)
Number of subjects: 286
Study: 11525450

Group type: EXPERIMENTAL
Intervention: Acellular allogeneic dermal connective tissue matrix (AD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Autogenous palatal connective tissue (CT)
Number of subjects: 22
Study: 9764980

Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: HCV-ISDR sequencing
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nucleotide substitution rate
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 13
Study: 7836526

Group type: EXPERIMENTAL
Intervention: Group A (co-cultured with cumulus cells)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Group B (dissected from cumulus cells)
Number of subjects: 550
Study: 2645886

Group type: EXPERIMENTAL
Intervention: Casein test meal
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Soybean test meal
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Protein free test meal
Number of subjects: 23
Study: 1098580

Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose heparin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Matched control (no heparin)
Number of subjects: 25
Study: 31838406

Group type: EXPERIMENTAL
Intervention: SCT + HDTp (Arm A)
Number of subjects: 44

Group type: COMPARATOR
Intervention: SCT alone (Arm B)
Number of subjects: 44
Study: 31219479

Group type: EXPERIMENTAL
Intervention: Real-world evidence (RWE)
Number of subjects: 0
Study: 28609389

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 0.45 mg/bazedoxifene 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 0.625 mg/bazedoxifene 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conjugated estrogens/MPA 1.5 mg
Number of subjects: 0
Study: 26416102

Group type: EXPERIMENTAL
Intervention: 1 × 10(4) PfSPZ in 50 μL/2 doses
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 × 10(4) PfSPZ in 10 μL/2 doses
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5 × 10(4) PfSPZ in 10 μL/8 doses
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5 × 10(4) PfSPZ in eight 10 μL injections
Number of subjects: 30
Study: 21504478

Group type: EXPERIMENTAL
Intervention: Milled bars (group I)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Telescopic crowns (group II)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Both groups (I and II)
Number of subjects: 51
Study: 20583956

Group type: EXPERIMENTAL
Intervention: Moxifloxacin monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 0
Study: 19095116

Group type: EXPERIMENTAL
Intervention: Continuous-wave Doppler ultrasound (UTS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Pulmonary artery catheter (PAC)
Number of subjects: 31
Study: 16045458

Group type: EXPERIMENTAL
Intervention: 480 mg cotrimoxazole (CTX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 960 mg cotrimoxazole (CTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unselected cohort from Zomba, Malawi (1995)
Number of subjects: 0

Group type: COMPARATOR
Intervention: National Tuberculosis Programme (1999)
Number of subjects: 0
Study: 11815892

Group type: EXPERIMENTAL
Intervention: Original grading
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regrading
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grading for 'confidence of tumor measurement'
Number of subjects: 0
Study: 10037245

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study: 7738533

Group type: EXPERIMENTAL
Intervention: Training on Piaget's horizontality task
Number of subjects: 122

Group type: COMPARATOR
Intervention: Pretest scores
Number of subjects: 122
Study: 2210587

Group type: EXPERIMENTAL
Intervention: Buscopan plus (hyoscine‐N‐butylbromide 30 mg/day + paracetamol 1500 mg/day)
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Buscopan (hyoscine‐N‐butylbromide 30 mg/day)
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Paracetamol (1500 mg/day)
Number of subjects: 712

Group type: COMPARATOR
Intervention: Placebo (3 tablets/day)
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Buscopan plus
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 712
Study: 6786132

Group type: EXPERIMENTAL
Intervention: Fresh gas flow of 130 ml/kg . min
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Fresh gas flow of 100 ml/kg . min
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Fresh gas flow of 70 ml/kg . min
Number of subjects: 7

Group type: COMPARATOR
Intervention: Conventional semi-closed anaesthesia circuit
Number of subjects: 7
Study: 31991116

Group type: EXPERIMENTAL
Intervention: PVI+FaST mapping/ablation
Number of subjects: 80

Group type: COMPARATOR
Intervention: PVI
Number of subjects: 80
Study: 31438489

Group type: EXPERIMENTAL
Intervention: Branded images of favourite food and beverage products
Number of subjects: 48

Group type: COMPARATOR
Intervention: Unpackaged counterparts of favourite food and beverage products
Number of subjects: 48
Study: 28759431

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid Extracellular Matrix and Compression Therapy
Number of subjects: 1

Group type: COMPARATOR
Intervention: Conventional treatments
Number of subjects: 1